Biovie (BIVI) Total Liabilities (2013 - 2026)
Biovie (BIVI) posted Total Liabilities of $1.9 million for Q1 2026, down 41.11% sequentially from $3.2 million in Q4 2025, and down 32.9% YoY from $2.8 million in Q1 2025.
Biovie (BIVI) Total Liabilities (2013 - 2026) Analysis & Trends
Biovie has reported Total Liabilities for 14 years, with the latest figure at $1.9 million in Q1 2026.
- Quarterly Total Liabilities fell 32.9% year-over-year to $1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 million (down 32.9% YoY) and the FY2025 annual result came in at $2.6 million, down 73.71% from the prior year.
- Total Liabilities fell to $1.9 million in Q1 2026 per BIVI's latest filing, from $3.2 million in the prior quarter.
- Over five years, Total Liabilities peaked at $23.5 million in Q1 2023 and troughed at $1.8 million in Q4 2024.
- A 5-year average of $11.1 million and a median of $12.8 million in 2024 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2022 and 2024: Total Liabilities soared 1550.35% in 2022, then plunged 87.34% in 2024.
- Over 5 years, Total Liabilities stood at $21.1 million in 2022, then tumbled by 33.73% to $14.0 million in 2023, then slumped by 87.34% to $1.8 million in 2024, then surged by 82.76% to $3.2 million in 2025, then tumbled by 41.11% to $1.9 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $1.9 million, $3.2 million, and $1.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.59 Bn | 131.73 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.21 Bn | 78.22 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.65 Bn | 60.47 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 57.67 Bn | 52.53 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.90 Bn | 9.51 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 10.03 Bn |
| 10 | Biovie | 13.77 Mn | 13.77 Mn | - | 3.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.98 Mn |
| Mar 31, 2026 | 1.91 Mn |
| Dec 31, 2025 | 3.24 Mn |
| Sep 30, 2025 | 1.90 Mn |
| Jun 30, 2025 | 2.55 Mn |
| Mar 31, 2025 | 2.84 Mn |
| Dec 31, 2024 | 1.77 Mn |
| Sep 30, 2024 | 7.17 Mn |
| Jun 30, 2024 | 9.70 Mn |
| Mar 31, 2024 | 12.85 Mn |
| Dec 31, 2023 | 14.00 Mn |
| Sep 30, 2023 | 16.21 Mn |
| Jun 30, 2023 | 19.76 Mn |
| Mar 31, 2023 | 23.46 Mn |
| Dec 31, 2022 | 21.12 Mn |
| Sep 30, 2022 | 16.90 Mn |
| Jun 30, 2022 | 16.44 Mn |
| Mar 31, 2022 | 16.23 Mn |
| Dec 31, 2021 | 15.81 Mn |
| Sep 30, 2021 | 1.74 Mn |